> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Paper on Designing Cell Therapies Future
- URL: https://www.fdaweb.com/paper-on-designing-cell-therapies-future/
- Published: 2019-05-21T12:00:00.000Z
- Updated: 2026-09-15T01:27:58.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5144158

A white paper, “Designing the Future of Cell Therapies,” produced by Friends of Cancer Research and the Parker Institute for Cancer Immunotherapy, says there is great interest in exploring new treatment modalities to encompass treatment of solid tumors, which comprise 90% of all cancers and the majority of cancer deaths. The [paper](https://www.focr.org/sites/default/files/pdf/Friends%5FCellular%5FTherapies%5FWhite%5FPaper.pdf?eType=EmailBlastContent&eId=7e1fee3f-287e-4dc4-89ac-e8548460e7fd&ref=fdaweb.com) says advancements in cancer immunology and recent clinical experience with emerging cellular therapeutics such as tumor infiltrating lymphocytes, engineered T-cell receptor, and chimeric antigen receptor T-cell therapies are generating huge interest and activity both academically and industrially.

To date, it says, FDA has only approved chimeric antigen receptor T-cell therapies for certain types of leukemia and lymphoma. It says that other T-cell therapies have shown remarkable activity in a limited number of solid tumors but have not yet progressed to FDA approval.

“Currently, multiple challenges exist for the successful use of T-cell-based therapies in solid tumors, including issues related to antigen selectivity and expression, the immunosuppressive nature of the tumor microenvironment, tumor T-cell infiltration, and the phenomenon of T-cell exhaustion,” the report says. “Academia and industry are working on multiple ideas to address these barriers, and numerous T-cell-based product candidates are being developed, involving various cell sub-types, autologous and allogenic approaches, various molecular manipulation strategies, and many different targets.”